A phase II study of anti-CTLA4 antibody [MDX 010; ipilimumab] in advanced synovial sarcoma patients

Trial Profile

A phase II study of anti-CTLA4 antibody [MDX 010; ipilimumab] in advanced synovial sarcoma patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2007

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top